ArticleFrontiers in pharmacology2024
Interplay of serum taurine, S-adenosylmethionine, and cysteine levels in cancer risk: a prospective study.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Smart responsive hydrogels combined with AI design for tumor therapy.Acta pharmaceutica Sinica. B · 2026Review
- A versatile method for designing biosensors via regulatory domains of allosteric enzymes.Nature communications · 2026Article
- Multi-phase hybrid metabolomics framework identifies clinically applicable plasma signatures for early detection of gastric cancer.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Amino acids are known to play critical roles in cancer metabolism and progression. Among them, taurine, S-adenosylmethionine (SAM), and cysteine have garnered particular attention due to their interconnected metabolic pathways. This study sought to explore the associations between serum levels of these amino acids and cancer risk within Chinese adults. Methods: A nested case-control study was conducted within the China H-Type Hypertension Registry Study cohort, comprising 1,391 cancer cases and 1,391 matched controls. Serum concentrations of taurine, SAM, and cysteine were quantified, and their associations with cancer risk were evaluated using conditional logistic regression and Bayesian Kernel Machine Regression (BKMR) models. Results: A total of 1,391 pairs of participants were included in this study. Their average age was 69.3 years ± 7.77 years, and 56% were male. Higher serum taurine levels were associated with a reduced risk of overall cancer. In contrast, elevated serum SAM levels were linked to an increased risk of digestive cancers. The BKMR model identified complex interactions among these amino acids and showed a significant overall negative association between the combined effect of taurine, SAM, and cysteine and cancer risk. Conclusion: Serum taurine levels may offer protective benefits against cancer, particularly for digestive cancers, while its metabolites do not have such significant benefits. The intricate interactions among taurine, SAM, and cysteine underscore the need for a comprehensive approach to understanding their roles in the metabolic processes that drive tumorigenesis. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=28262, identifier ChiCTR1800017274.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.